AbbVie to Present Phase 3 Etentamig Results and Data from Broad Multiple Myeloma Portfolio at the 2026 International Myeloma Society (IMS) Meeting

• Plenary presentation will feature Phase 3 CERVINO results demonstrating that etentamig met the study's dual primary endpoints of objective response rate (ORR) and progression-free survival (PFS) in relapsed/refractory multiple myeloma (RRMM)

• Additional presentations highlight research across the breadth of AbbVie's multiple myeloma portfolio, including ABBV-2001 (ISB 2001), a trispecific T-cell engager and surzetoclax, a BCL-2 inhibitor, and combination approaches

• AbbVie's IMS presence reinforces its strategy to build a differentiated multiple myeloma portfolio across complementary mechanisms designed to address disease complexity and evolving patient needs

NORTH CHICAGO, Ill., Sept. 17, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that new data from its broad multiple myeloma research portfolio will be featured at the 23 rd International Myeloma Society (IMS) Annual Meeting, taking place September 23-26, 2026, in Glasgow, Scotland. A plenary presentation will feature full results from the Phase 3 CERVINO study evaluating investigational drug etentamig, a second-generation BCMA x CD3 bispecific T-cell engager. Topline results demonstrated statistically significant and clinically meaningful improvements in objective response rate (ORR) and progression-free survival (PFS), with etentamig meeting the dual primary endpoints versus standard available therapies in adults with triple-class exposed relapsed/refractory multiple myeloma (RRMM).

Beyond the full CERVINO data, AbbVie will present research demonstrating the breadth of its myeloma pipeline across T-cell engagers, targeted therapies, rational combinations and real-world evidence. Presentations will feature investigational assets including ABBV-2001 (ISB 2001), a CD38 x BCMA x CD3 trispecific T-cell engager, and surzetoclax, a BCL-2 small-molecule inhibitor, alongside studies evaluating etentamig across multiple treatment settings.

Additional presentations from these investigational assets will explore treatment sequencing, infection-related healthcare utilization and costs, and real-world outcomes, reinforcing AbbVie's strategy to advance understanding of disease heterogeneity, mechanisms of resistance and the evolving needs of patients living with multiple myeloma.

"Despite meaningful progress in multiple myeloma, the disease remains incurable and patients continue to face challenges related to treatment resistance, disease heterogeneity, tolerability and durable disease control," said Daejin Abidoye, M.D., vice president and therapeutic area head, oncology, solid tumor and hematology at AbbVie. "Our presence at IMS reflects the depth and momentum of our multiple myeloma strategy as we advance our scientifically differentiated portfolio, spanning T-cell engagers, targeted therapies and rational combinations designed to address distinct disease mechanisms and evolving patient needs, with the goal of delivering more precise, durable and accessible treatment options."

The full list of AbbVie presentations at IMS includes:

Note: All presentation times are listed in local Glasgow time.

Real-World (RW) Characteristics, Treatment

Patterns, and Outcomes in Triple-Class Exposed

(TCE) Relapsed/Refractory Multiple Myeloma

(RRMM) in Europe: Results from the HARMONY Big

Data Platform

Wednesday, September 23, 2026

12:00–1:00 PM

Poster Presentation

PA-386

Etentamig in Patients with Relapsed/Refractory

Multiple Myeloma (RRMM) with Prior Exposure to B- Cell Maturation Antigen (BCMA)-Targeted Therapy

Thursday, September 24, 2026

12:00–1:00 PM

Poster Presentation

PA-181

A Phase 1/2, Open-Label, Platform Study to

Evaluate the Safety and Efficacy of Etentamig

Monotherapy or Combination Therapy in Patients with Multiple Myeloma

Friday, September 25, 2026

12:00–1:00 PM

Poster Presentation

PA-008

Phase 1/2, Open-Label, Platform Study of Surzetoclax with Etentamig in Biomarker-

Selected Patients with Relapsed/Refractory

Multiple Myeloma (RRMM)

Friday, September 25, 2026

12:00–1:00 PM

Poster Presentation

PA-346

Real-World (RW) Infection-Related Healthcare Resource Utilization (HCRU) and Costs in Patients (pts) with Multiple Myeloma (MM) Receiving

T-cell Redirecting Therapies (TCRTs)

Friday, September 25, 2026

12:00–1:00 PM

Poster Presentation

PA-387

CERVINO: Phase (Ph) 3 Results of Etentamig vs

Investigator's Choice of Standard Available

Therapies (SAT) in Patients (Pts) With Triple- Class

Exposed Relapsed or Refractory Multiple Myeloma

(RRMM)

Friday, September 25, 2026

3:00–5:00 PM

Plenary Session

Hall 5

LBA-01

Etentamig Combined With Pomalidomide Plus

Dexamethasone (Pom+Dex) in Relapsed/

Refractory Multiple Myeloma (RRMM) After 1–3

Prior Lines of Therapy: A Phase 1b Dose- Escalation and Safety Expansion Study

Saturday, September 26, 2026

8:30–9:30 AM

Oral Presentation

Abstract Session 9

Hall 5

OA-24

AbbVie Advances ABBV- 2001/ISB 2001: A Unique, Single-Molecule Trispecific T-cell Engager (TCE) Approach Toward Robust Anti-Myeloma Activity with Superior Tumor Cytotoxicity

Saturday, September 26, 2026

9:30–10:20 AM

Oral Presentation

Future Targets and New Modalities of Therapy

Hall 5

N/A

Surzetoclax: A Potentially Best-in-Class BCL-2

Inhibitor for the Treatment of Multiple Myeloma

with t(11;14) Translocation or High BCL-2

Expression

N/A

Poster Presentation

PA-468

More information about the IMS 2026 meeting, including AbbVie's presence, will be available here.

Additional information around AbbVie's ongoing clinical trials in multiple myeloma can be found at clinicaltrials.gov.

Etentamig, ABBV-2001 (ISB 2001) and surzetoclax are investigational medicines and are not approved by any health authorities worldwide. The safety and efficacy of these investigational medicines are under evaluation as part of ongoing clinical studies.

AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.

AbbVie is committed to elevating standards of care and bringing transformative therapies to patients worldwide living with difficult-to-treat cancers. We are advancing a dynamic pipeline of investigational therapies across a range of cancer types in both blood cancers and solid tumors. We are focusing on creating targeted medicines that either impede the reproduction of cancer cells or enable their elimination. We achieve this through various targeted treatment modalities and biology interventions, including small molecule therapeutics, antibody-drug conjugates (ADCs), immuno-oncology-based therapeutics, multispecific antibodies and novel CAR-T platforms. Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potential breakthrough medicines.

Today, our expansive oncology portfolio comprises approved and investigational treatments for a wide range of blood cancers and solid tumors. We are evaluating more than 35 investigational medicines in multiple clinical trials across some of the world's most widespread and debilitating cancers. As we work to have a remarkable impact on people's lives, we are committed to exploring solutions to help patients obtain access to our cancer medicines. For more information, please visit http://www.abbvie.com/oncology.

Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2025 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

Media:

Sourojit (Jit) Bhowmick, Ph.D.

[email protected]

Investors:

Liz Shea

[email protected]